

Summary of NICE Guidelines

Title	Retigabine for the adjunctive treatment of partial onset seizures in Epilepsy
NICE Reference	TA 232
Date of Review:	December 2014
Date of Publication	July 2011
Summary of Guidance (Max 250 words)	<ul style="list-style-type: none"> • Some people with partial onset seizures in epilepsy do not achieve an adequate clinical response with currently available treatments. • Retigabine has a novel mode of action and is now recommended as an adjunctive treatment in people whose epilepsy is resistant to current therapies. • Patients may require an ECG prior to starting treatment to monitor the risk of QT prolongation and cardiac events.
Impact on Lab (See below)	<input checked="" type="checkbox"/> None
Lab professionals to be made aware	
Please detail the impact of this guideline (Max 150 words)	No impact

Impact on Lab

- None:** This NICE guideline has no impact on the provision of laboratory services
- Moderate:** This NICE guideline has information that is of relevance to our pathology service and may require review of our current service provision.
- Important:** This NICE guideline is of direct relevance to our pathology service and will have a direct impact on one or more of the services that we currently offer.

Written by: Miss Stephanie Carter
Reviewed by: Dr Maureen Leonard